Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.98M | 13.88M | 9.68M | 8.47M | 6.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.34M | 38.28M | 41.13M | 46.75M | 44.45M |
| Operating Income | -45.34M | -38.28M | -41.13M | -46.75M | -44.45M |
| Income Before Tax | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M |
| EBIT | -45.34M | -38.28M | -41.13M | -46.75M | -44.45M |
| EBITDA | -45.33M | -38.27M | -41.12M | -46.73M | -44.43M |
| EPS Basic | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 |
| Normalized Basic EPS | -0.30 | -0.25 | -0.33 | -0.41 | -0.50 |
| EPS Diluted | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 |
| Normalized Diluted EPS | -0.30 | -0.25 | -0.33 | -0.41 | -0.50 |
| Average Basic Shares Outstanding | 82.83M | 80.55M | 70.59M | 65.45M | 53.16M |
| Average Diluted Shares Outstanding | 82.83M | 80.55M | 70.59M | 65.45M | 53.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |